New Topical Treatment for Actinic Keratosis Granted FDA Approval pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp Actinic keratosis is the second most common diagnosis made by dermatologists in the United States1 In one of the largest Phase III clinical study programs2 ever conducted for a topical AK treatment, tirbanibulin demonstrated complete clearance of actinic keratosis lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle Klisyri has a demonstrated safety profile with no patient withdrawals due to adverse events, and a convenient 5-day application period which is the shortest of any topical treatment for AK